drugset / Trial / NCT03752541
Efficacy and Safety Evaluation of BCMA-UCART
Suspended
20 enrolled
Bioray Laboratories
Second Xiangya Hospital of Central South University · collabShanghai Tongji Hospital, Tongji University School of Medicine · collab
NaSequentialOpen-labelTreatment
Summary
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2023-03-20
- Completion
- 2023-11-20
Outcome
Outcome not reported
Stopped: “decided by the sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA-UCART | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | BCMA-UCART | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | BCMA-UCART | Cell therapy | 2e+06 cells/kg | Intravenous |